

Randox licenses sPLA2 CVD risk test from Aterovax, 8/13:87

Randox Laboratories and Aterovax have announced a strategic partnership to commercialize Aterovax's secreted phospholipase A2 (sPLA2) biomarker for the assessment of cardiovascular risk. Terms of the alliance were not disclosed.

SPLA2 is a novel biomarker that independently predicts adverse outcomes in patients with stable coronary artery disease and is useful in the risk stratification of patients with acute coronary syndrome.

Randox has exclusive rights to develop, manufacture, and market the new test for use on automated immunoassay analyzers and will develop the sPLA2 test for its own analyzers and other diagnostic analyzers.

[Randox Laboratories](#), 304-728-2890